Ask about this productRelated genes to: LAIR1 protein
- Gene:
- LAIR1 NIH gene
- Name:
- leukocyte associated immunoglobulin like receptor 1
- Previous symbol:
- -
- Synonyms:
- CD305
- Chromosome:
- 19q13.42
- Locus Type:
- gene with protein product
- Date approved:
- 1997-07-25
- Date modifiied:
- 2016-10-05
Related products to: LAIR1 protein
Related articles to: LAIR1 protein
- Lung adenocarcinoma (LUAD) is the most common lung cancer histological subtype. Although the unfolded protein response (UPR) has been linked to various human diseases, its role in LUAD remains unclear. To identify UPR-related genes, we applied various methods, including weighted gene co-expression network analysis, differential expression analysis, and multivariate Cox regression. Ten machine learning algorithms were used to construct a UPR-related signature (UPRRS), which was validated using multiple public LUAD datasets. The UPRRS was integrated into a nomogram used in clinical practice for prognosis prediction. We also evaluated predicted drug sensitivity patterns across different risk subgroups. We identified 33 UPR-associated hub genes. A UPRRS was developed through systematic evaluation of 101 machine-learning combinations, exhibiting stable prognostic performance across multiple cohorts. Integration of the UPRRS into a nomogram facilitated the construction of a quantitative prognostic model. Significant differences in biological processes and tumor microenvironment immune cell infiltration were observed between the high- and low-risk UPRRS groups. All five UPRRS genes (ALDH2, FKBP4, KLF4, LAIR1, SIDT2) were validated at the protein level in LUAD cell lines, and FKBP4 was further confirmed by IHC in clinical tissues. Functional experiments showed that FKBP4 knockdown inhibited proliferation, migration, and invasion of A549 and H1975 cells, supporting a potential role for FKBP4 in LUAD progression. Our UPRRS provides a promising tool for prognostic stratification and may offer additional insights into tumor immune microenvironment characterization and therapeutic response prediction in LUAD. - Source: PubMed
Publication date: 2026/07/04
Jiao RuiWu ChengyangZhang TaoYan HanyuHe WeidongWang ZhaoyangYan Xiaolong - Atherosclerosis (AS) is a common complication of lung adenocarcinoma (LUAD), but its underlying mechanisms in LUAD remain unclear. This study aimed to decipher the role of chromatin regulators in AS pathogenesis and their association with clinical outcomes in LUAD patients. AS- and chromatin regulator (CR)-associated prognostic indicators were identified in LUAD and analyzed in the TCGA-LUAD cohort using Cox regression and Disease Ontology analysis. CR-related risk subgroups were defined by NMF in the GSE26939 cohort. GSVA and WGCNA, combined with interpretable machine learning, were used to construct a predictive model and identify key genes, which were validated in GSE68465. The molecular features of key genes and their roles in AS were further evaluated. Besides, mechanisms of key genes in M2-like macrophages were assessed at the single-cell level in LUAD patients using cutting-edge analytical frameworks. A deep learning framework and molecular docking were used to screen natural compounds. Finally, co-culture experiments were conducted for validation. CR signatures can guide the LUAD patients LUAD patients into high- and low-AS risk groups and were associated with clinical outcomes. LAIR1 can be considered as an AS-related factor enriched in M2-like macrophages and involved in LUAD progression. Quercetin was identified as potential preventive agent for AS in LUAD patients. CR-associated signatures play an important role in AS pathogenesis and LUAD progression. - Source: PubMed
Publication date: 2026/06/19
Zhang ChuanqiChen BoLi ZheLi XianweiJiang Weiliang - The role of leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) in immune regulation has been documented, yet its function in gastric cancer (GC) pathogenesis is not well defined. This study sought to evaluate the prognostic relevance and biological influence of LAIR1 in GC development and dissemination. - Source: PubMed
Publication date: 2026/04/30
Shu XufengYuan ChendongWang XiaoqiangXiong JianboChen WenzhengZhang GuoyangJie Zhigang - This research is designed to establish a prognostic framework derived from m6A- and autophagy-related lncRNAs (m6aARLncs) to enhance survival prediction in esophageal squamous cell carcinoma (ESCC). Concurrently, it endeavors to elucidate the role of prognostic framework in modulating the tumor immune microenvironment. - Source: PubMed
Publication date: 2026/05/28
Yang MingyiRen HonghaoHu JingWen PengfeiXie JialeWan XianjieLiu LinYang ZhiZhang MingRen XiaodongSu Yani - Lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus (SLE), features heterogeneous renal pathology and reliance on invasive biopsies for diagnosis, prognosis, and treatment selection. Current peripheral clinical markers inadequately capture disease activity and progression. Here, we performed comprehensive serum proteomic profiling of over 5,000 proteins in the large, longitudinal Accelerating Medicines Partnership Rheumatoid Arthritis/SLE cohort of 270 LN patients and 63 healthy controls. Machine learning identified distinct molecular signatures that classified LN versus controls, differentiated histological classes, and delineated activity- and chronicity-associated pathways, including inflammatory cytokine, PI3K/AKT, TGFb, and complement/coagulation pathways. An increase in VSIG4, CD27, HAVCR1, and LAIR1 consistently emerged as top biomarkers across multiple clinical contexts, and early decreases in these markers at 3 months were associated with complete treatment response at 1 year. By resolving coordinated serum protein modules linked to key inflammatory, PI3K/AKT, TGFb, and complement pathways, these signatures mechanistically connect circulating proteomic perturbations to intrarenal immune activation, tissue injury, and repair in LN. These findings demonstrate that serum proteomics reflect complex intrarenal immunopathology and offer a promising noninvasive "liquid biopsy" approach to refine LN classification and guide personalized management, potentially reducing the need for repeated invasive biopsies and improving therapeutic decision-making. - Source: PubMed
Publication date: 2026/05/12
Lu RufeiWagner Catriona AFava AndreaJones BenIzmirly PeterBelmont H MichaelClancy Robert MAnolik JenniferBarnas Jennifer LPutterman ChaimWofsy DavidWeisman Michael HDavidson AnneFine Derek MHolers V MichaelUtz Paul J Diamond BettyBuyon JillPetri MichelleGuthridge Joel MJames Judith A